Ionis Sells Kynamro To Kastle After Regaining Rights From Genzyme
Three and a half months after Ionis Pharmaceuticals Inc. surprised investors with the news that Sanofi's Genzyme business unit would no longer market Kynamro (mipomersen) for homozygous familial hypercholesterolemia (HoFH), the Carlsbad, California-based biotechnology company revealed that it sold global rights to the cholesterol-lowering drug to Kastle Therapeutics LLC for up to $95m.
You may also be interested in...
Despite complete response letter for Akcea's Waylivra, RNA therapeutics may have regulatory pathway to approval for lipid disorders.
Spinraza, launched by partner Biogen, is the antisense developer’s newest drug to reach the market. Ionis plans to file its first wholly-owned drug, volanesorsen, later this year.
Both companies’ stocks surged Nov. 7 on positive data from a second Phase III trial showing the antisense drug improved motor function in children with later onset spinal muscular atrophy.